Off-Label Uses of Abrocitinib: Review of Emerging Therapeutic Applications Beyond Atopic Dermatitis

Abrocitinib, a JAK1 inhibitor approved for atopic dermatitis, is being explored for off-label use in various dermatological conditions, including alopecia areata, vitiligo, and prurigo nodularis. This review analyzed 37 papers involving 103 patients, showing promising results, particularly in cases where other treatments failed. Most cases reported favorable outcomes, with significant improvements noted in conditions like vitiligo and alopecia areata. Adverse effects were generally mild, but the findings are limited by small sample sizes and lack of rigorous controls. Larger, randomized controlled trials are needed to confirm Abrocitinib's safety and efficacy across these conditions.